Roche Holding AG (OTCMKTS:RHHBY) – Analysts at Jefferies Group increased their FY2021 EPS estimates for shares of Roche in a report released on Friday, April 13th. Jefferies Group analyst I. Hilliker now expects that the company will post earnings of $2.77 per share for the year, up from their prior estimate of $2.69. Jefferies Group also issued estimates for Roche’s FY2022 earnings at $3.06 EPS.

How to Become a New Pot Stock Millionaire

A number of other equities analysts also recently commented on RHHBY. Zacks Investment Research downgraded shares of Roche from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Societe Generale downgraded shares of Roche from a “hold” rating to a “sell” rating in a research note on Monday, January 15th. JPMorgan Chase reissued an “overweight” rating on shares of Roche in a research note on Friday, December 29th. ValuEngine raised shares of Roche from a “hold” rating to a “buy” rating in a research note on Tuesday, January 16th. Finally, Morgan Stanley downgraded shares of Roche from an “equal weight” rating to an “underweight” rating in a research note on Tuesday, March 27th. Four equities research analysts have rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $35.00.

Shares of RHHBY opened at $28.21 on Monday. The firm has a market capitalization of $192,194.73, a price-to-earnings ratio of 14.47, a P/E/G ratio of 1.75 and a beta of 0.55. Roche has a fifty-two week low of $27.65 and a fifty-two week high of $36.82. The company has a current ratio of 1.42, a quick ratio of 1.09 and a debt-to-equity ratio of 0.55.

A number of institutional investors have recently added to or reduced their stakes in RHHBY. Sterling Capital Management LLC increased its stake in Roche by 4.6% during the 3rd quarter. Sterling Capital Management LLC now owns 58,107 shares of the company’s stock worth $1,856,000 after buying an additional 2,535 shares during the period. Chickasaw Capital Management LLC increased its stake in Roche by 33.3% during the 4th quarter. Chickasaw Capital Management LLC now owns 40,000 shares of the company’s stock worth $1,265,000 after buying an additional 10,000 shares during the period. New England Research & Management Inc. increased its stake in Roche by 11.6% during the 4th quarter. New England Research & Management Inc. now owns 26,257 shares of the company’s stock worth $829,000 after buying an additional 2,730 shares during the period. Gofen & Glossberg LLC IL purchased a new stake in Roche during the 4th quarter worth $267,000. Finally, Jolley Asset Management LLC increased its stake in Roche by 38.8% during the 4th quarter. Jolley Asset Management LLC now owns 64,515 shares of the company’s stock worth $2,040,000 after buying an additional 18,050 shares during the period. 0.57% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Roche Holding AG (RHHBY) to Post FY2021 Earnings of $2.77 Per Share, Jefferies Group Forecasts” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2018/04/16/roche-holding-ag-rhhby-to-post-fy2021-earnings-of-2-77-per-share-jefferies-group-forecasts.html.

About Roche

Roche Holding AG diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases.

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.